Literature DB >> 23441960

Guidelines for the diagnosis and treatment of vitiligo in Japan.

Naoki Oiso1, Tamio Suzuki, Mari Wataya-Kaneda, Atsushi Tanemura, Miki Tanioka, Tomoko Fujimoto, Kazuyoshi Fukai, Tamihiro Kawakami, Katsuhiko Tsukamoto, Yuji Yamaguchi, Shigetoshi Sano, Yoshihiko Mitsuhashi, Chikako Nishigori, Akimichi Morita, Hidemi Nakagawa, Masako Mizoguchi, Ichiro Katayama.   

Abstract

Vitiligo is an acquired pigment disorder in which depigmented macules result from the loss of melanocytes from the involved regions of skin and hair. The color dissimilarity on the cosmetically sensitive regions frequently induces quality of life impairment and high willingness to pay for treatment in patients with vitiligo. The Vitiligo Japanese Task Force was organized to overcome this situation and to cooperate with the Vitiligo Global Issues Consensus Conference. This guideline for the diagnosis and treatment of vitiligo in Japan is proposed to improve the circumstances of Japanese individuals with vitiligo. Its contents include information regarding the diagnosis, pathogenesis, evaluation of disease severity and effectiveness of treatment, and evidence-based recommendations for the treatment of vitiligo. The therapeutic algorithm based on the proposed recommendation is designed to cure and improve the affected lesions and quality of life of individuals with vitiligo.
© 2013 Japanese Dermatological Association.

Entities:  

Mesh:

Year:  2013        PMID: 23441960     DOI: 10.1111/1346-8138.12099

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  10 in total

Review 1.  Melanocytes and their diseases.

Authors:  Yuji Yamaguchi; Vincent J Hearing
Journal:  Cold Spring Harb Perspect Med       Date:  2014-05-01       Impact factor: 6.915

Review 2.  Current Management of Pediatric Vitiligo.

Authors:  Freya Van Driessche; Nanette Silverberg
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

3.  In Vitro TyRP-1 Knockdown Based on siRNA Carried by Liquid Crystalline Nanodispersions: an Alternative Approach for Topical Treatment of Vitiligo.

Authors:  Larissa Bueno Tofani; Lívia Vieira Depieri; Patrícia Mazureki Campos; Thalita Bachelli Riul; Kamilla Swiech Antonietto; Márcia Carvalho de Abreu Fantini; Maria Vitória Lopes Badra Bentley
Journal:  Pharm Res       Date:  2018-03-20       Impact factor: 4.200

4.  Patients' Perception of Vitiligo Severity.

Authors:  Nanja van Geel; Charlotte Moock; Marloes Zuidgeest; Sanne Elisabeth Uitentuis; Albert Wolkerstorfer; Reinhart Speeckaert
Journal:  Acta Derm Venereol       Date:  2021-06-28       Impact factor: 3.875

5.  Fabrication of anti-vitiligo ointment containing Psoralea corylifolia: in vitro and in vivo characterization.

Authors:  Irshad Hussain; Nisar Hussain; Abdul Manan; Abdur Rashid; Barkat Khan; Sattar Bakhsh
Journal:  Drug Des Devel Ther       Date:  2016-11-22       Impact factor: 4.162

6.  Chronic diseases among vitiligo patients. A case control study.

Authors:  Abdullah O Al Houssien; Rana O Al Houssien; Waleed Al Ajroush; Hassan S Al Kahtani
Journal:  Saudi Med J       Date:  2017-04       Impact factor: 1.484

Review 7.  Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits.

Authors:  Mamitaro Ohtsuki; Hiroshi Morimoto; Hidemi Nakagawa
Journal:  J Dermatol       Date:  2018-06-21       Impact factor: 4.005

8.  Tracing the Photoaddition of Pharmaceutical Psoralens to DNA.

Authors:  Janina Diekmann; Isabell Theves; Kristoffer A Thom; Peter Gilch
Journal:  Molecules       Date:  2020-11-10       Impact factor: 4.411

9.  Meta-analysis of the efficacy of adding platelet-rich plasma to 308-nm excimer laser for patients with vitiligo.

Authors:  Jiaoquan Chen; Nanji Yu; Huaping Li; Yi Tang; Huilan Zhu
Journal:  J Int Med Res       Date:  2022-09       Impact factor: 1.573

10.  Fibromyalgia Syndrome and Vitiligo: A Novel Association.

Authors:  Oula S Khudhair; Faiq I Gorial; Ammar F Hameed
Journal:  Arch Rheumatol       Date:  2017-10-16       Impact factor: 1.472

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.